Next Article in Journal
The Impact of Silver Nanoparticles Functionalized with Spirulina Protein Extract on Rats
Next Article in Special Issue
An Antagonist Antibody That Inhibits Cancer Cell Growth In Vitro through RACK1
Previous Article in Journal
Molecular Targets of Minor Cannabinoids in Breast Cancer: In Silico and In Vitro Studies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 9
10.3390/ph17091246
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy

by
Hideki Tanaka
1,2,
Yoshikatsu Koga
3,
Mayumi Sugahara
4,
Hirobumi Fuchigami
5,
Akihiro Ishikawa
6,
Toru Yamaguchi
6,
Akiko Banba
6,
Takeshi Shinozaki
1,
Kazuto Matsuura
1,
Ryuichi Hayashi
1,
Shingo Sakashita
7,
Masahiro Yasunaga
5 and
Tomonori Yano
4,8,*
1
Department of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
2
Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Shinjuku 160-0022, Japan
3
Department of Strategic Programs, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan
4
Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
5
Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan
6
Shimadzu Corporation, Kyoto 604-8511, Japan
7
Division of Developmental Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan
8
Division of Science and Technology for Endoscopy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(9), 1246; https://doi.org/10.3390/ph17091246
Submission received: 11 August 2024 / Revised: 16 September 2024 / Accepted: 17 September 2024 / Published: 22 September 2024
(This article belongs to the Special Issue Evaluation of the Antitumor Mechanism of Armed Antibodies: 2nd Edition)
Browse Figures
Versions Notes

Abstract

Background/Objectives: Near-infrared photoimmunotherapy (NIR-PIT) was recently approved for the treatment of unresectable locally advanced or recurrent head and neck cancers in Japan; however, only one clinical dose has been validated in clinical trials, potentially resulting in excessive or insufficient dosing. Moreover, IRDye700X (IR700) fluorescence intensity plateaus during treatment, indicating a particular threshold for the antitumor effects. Therefore, we investigated the NIR laser dose across varying tumor sizes and irradiation methods until the antitumor effects of the fluorescence decay rate plateaued. Methods: Mice were subcutaneously transplanted with A431 xenografts and categorized into control, clinical dose (cylindrical irradiation at 100 J/cm², frontal irradiation at 50 J/cm²), and evaluation groups. The rate of tumor IR700 fluorescence intensity decay to reach predefined rates (−0.05%/s or −0.2%/s) until the cessation of light irradiation was calculated using a real-time fluorescence imaging system. Results: The evaluation group exhibited antitumor effects comparable to those of the clinical dose group at a low irradiation dose. Similar results were observed across tumor sizes and irradiation methods. Conclusions: In conclusion, the optimal antitumor effect of NIR-PIT is achieved when the fluorescence decay rate reaches a plateau, indicating the potential to determine the appropriate dose for PIT using a real-time fluorescence monitoring system.
Keywords: photoimmunotherapy; fluorescence imaging; real-time imaging; IR700; antibody–drug conjugate; anticancer therapy photoimmunotherapy; fluorescence imaging; real-time imaging; IR700; antibody–drug conjugate; anticancer therapy

Share and Cite

MDPI and ACS Style

Tanaka, H.; Koga, Y.; Sugahara, M.; Fuchigami, H.; Ishikawa, A.; Yamaguchi, T.; Banba, A.; Shinozaki, T.; Matsuura, K.; Hayashi, R.; et al. Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy. Pharmaceuticals 2024, 17, 1246. https://doi.org/10.3390/ph17091246

AMA Style

Tanaka H, Koga Y, Sugahara M, Fuchigami H, Ishikawa A, Yamaguchi T, Banba A, Shinozaki T, Matsuura K, Hayashi R, et al. Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy. Pharmaceuticals. 2024; 17(9):1246. https://doi.org/10.3390/ph17091246

Chicago/Turabian Style

Tanaka, Hideki, Yoshikatsu Koga, Mayumi Sugahara, Hirobumi Fuchigami, Akihiro Ishikawa, Toru Yamaguchi, Akiko Banba, Takeshi Shinozaki, Kazuto Matsuura, Ryuichi Hayashi, and et al. 2024. "Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy" Pharmaceuticals 17, no. 9: 1246. https://doi.org/10.3390/ph17091246

APA Style

Tanaka, H., Koga, Y., Sugahara, M., Fuchigami, H., Ishikawa, A., Yamaguchi, T., Banba, A., Shinozaki, T., Matsuura, K., Hayashi, R., Sakashita, S., Yasunaga, M., & Yano, T. (2024). Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy. Pharmaceuticals, 17(9), 1246. https://doi.org/10.3390/ph17091246

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop